#USA #New York #Pomerantz #Globus Medical #GMED

Investor Alert: Investigation into Globus Medical, Inc. (GMED)

The Pomerantz Law Firm has initiated a comprehensive investigation into Globus Medical, Inc. (NYSE: GMED) on behalf of its investors. This inquiry follows claims that the company, along with certain officers and directors, may have engaged in securities fraud or other illicit business practices, leading to significant financial losses among its shareholders.

Context of the Investigation

On May 8, 2025, Globus released its financial results for the first quarter of 2025. Despite analysts' expectations, the company reported non-GAAP earnings per share of $0.68, which fell short by $0.06 compared to consensus estimates. Furthermore, they reported revenues of $598.12 million, missing expectations by approximately $27.78 million, and reflected a year-over-year decline of 1.4%. The President and CEO of Globus attributed these disappointing results to a combination of sluggish Enabling Technology deal closures, temporary supply chain disruptions due to integration, and delays in international distributor orders.

On the heels of this news, Globus’s stock price experienced a substantial downturn, plummeting by $16.64, equivalent to a staggering 22.96% drop. This drastic decline left investors deeply concerned about the underlying practices of the company and its leadership.

The Role of Pomerantz LLP

Founded by Abraham L. Pomerantz, a pioneer in class-action litigation, Pomerantz LLP is well-regarded in the field of corporate law, particularly in protecting the rights of investors who have suffered due to securities fraud. The firm has a long history of successfully securing multi-million dollar settlements on behalf of its clients. Today, Pomerantz continues to stand up for the victims of corporate misconduct, striving for justice and transparency in the market.

The firm's prominent presence in key cities—New York, Chicago, Los Angeles, London, Paris, and Tel Aviv—underscores its commitment to serving clients on a global scale. The current investigation aims to explore whether the actions taken by Globus Medical reflect a pattern of deceptive practices that violated securities laws.

What Investors Should Do

Investors who believe they have incurred losses due to Globus Medical’s actions are encouraged to reach out to Pomerantz LLP. They can contact attorney Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980. In addition, potential plaintiffs are advised to consider joining any class action that may arise from this inquiry, as collective action can often strengthen claims against companies alleged to have committed fraud.

As this investigation unfolds, shareholders will be watching closely for any developments. The outcome may have significant implications for both Globus Medical and the broader market, reminding investors of the critical importance of corporate governance and ethical business practices.

Conclusion

The investigation into Globus Medical Inc. is a reminder of the vital role that law firms like Pomerantz play in maintaining the integrity of the financial markets. As they pursue justice on behalf of the investors harmed by alleged fraud, the firm will likely shed light on the processes and decisions that led to such significant financial repercussions. Investors are encouraged to stay informed and consider their next steps carefully as this situation develops.